Abstract Number: 344 • 2019 ACR/ARP Annual Meeting
Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial
Background/Purpose: Rotator cuff calcific tendinopathy is a common condition causing up to 20% of the painful shoulder. Ultrasound guided percutaneous lavage (UGPL) is indicated after…Abstract Number: 345 • 2019 ACR/ARP Annual Meeting
Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey
Background/Purpose: The cardiovascular risk of gout is already well known, and the debate over the cardiovascular risk of uric acid lower agents is currently hot.…Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…Abstract Number: 347 • 2019 ACR/ARP Annual Meeting
Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease
Background/Purpose: Atlantoaxial joint involvement in calcium pyrophosphate deposition disease (CPPD) may present as crowned dens syndrome (CDS), a clinico-radiological tetrad defined as the presence of…Abstract Number: 348 • 2019 ACR/ARP Annual Meeting
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Background/Purpose: A variety of newer gout therapies have been introduced in recent years, some with potential safety concerns. However, uptake of these therapies and associated…Abstract Number: 349 • 2019 ACR/ARP Annual Meeting
Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study
Background/Purpose: Carotid subclinical atherosclerosis is prevalent in patients with gout, although poorly predicted by cardiovascular risk assessment tools. Gout itself is deemed to contribute to…Abstract Number: 350 • 2019 ACR/ARP Annual Meeting
Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events
Background/Purpose: A recent study showed that febuxostat had a higher risk of cardiovascular and all-cause mortality than allopurinol. Because febuxostat is more potent than allopurinol,…Abstract Number: 351 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City
Background/Purpose: Allopurinol (ALLO), the leading hypouricemic drug worldwide, exposes to mild (M) and severe (S) cutaneous adverse reactions (CARs). SCARS have been associated with HLA*B-58…Abstract Number: 352 • 2019 ACR/ARP Annual Meeting
Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis
Background/Purpose: Studies have suggested that primary hyperparathyroidism could be a risk factor for hyperuricemia although the results were inconsistent across the studies. This systematic review…Abstract Number: 353 • 2019 ACR/ARP Annual Meeting
Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study
Background/Purpose: Several studies implicate gout and/or xanthine oxidase activity as risk factors for type 2 diabetes. However, no studies have directly evaluated the effect of…Abstract Number: 354 • 2019 ACR/ARP Annual Meeting
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Background/Purpose: The Opioid Epidemic has been declared a public health emergency since 2017. The use of opioids in the acute crystal induced arthritis (ACIA) population…Abstract Number: 355 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Background/Purpose: Gout is the most common inflammatory arthritis and is particularly common among veterans. Recent studies, a randomized controlled trial (CARES, White et al. NEJM…Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…Abstract Number: 357 • 2019 ACR/ARP Annual Meeting
Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Background/Purpose: Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based…Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…
ACR Meeting Abstracts